LONDON, ONTARIO -- (MARKET WIRE) -- November 07, 2006 -- Critical Outcome Technologies Inc. (TSX VENTURE: COT), a computational drug discovery and pre-clinical drug development company, has completed the discovery, optimization and final selection of its library of lead compounds for the oral treatment of acute Multiple Sclerosis. The compounds have been engineered to be orally available, have low toxicity, cross the blood brain barrier and selectively inhibit Vascular Endothelial Growth Factor (VEGF-R) and Platelet Derived Growth Factor (PDGF-R) receptor kinases.
